BREAST CANCER:
FROM MOLECULAR SIGNATURES TO
CLINICAL ONCOLOGY
HOTEL NH PARMA 21 GIUGNO 2019
PRESIDENTE
ANTONINO MUSOLINO
Responsabile del programma Breast Unit Azienda Ospedaliero-Universitaria di Parma
SEDE
HOTEL NH PARMA Viale Paolo Borsellino, 31 43122 Parma PR ISCRIZIONE
L’iscrizione è gratuita previa registrazione online effettuabile dal sito www.mitcongressi.it sezione:
BREAST CANCER: FROM MOLECULAR SIGNATURES TO CLINICAL ONCOLOGY
ECM
Sono stati richiesti X crediti per:
Medico Chirurgo (discipline ...)
SEGRETERIA ORGANIZZATIVA
MI&T srl Viale Carducci 50 - 40125 Bologna - Tel. 051 220427 [email protected] - www.mitcongressi.it
PROGETTO FORMAZIONE GOIRC
9.30 INTRODUCTION Antonino Musolino
10.00 PHENOTYPIC HETEROGENEITY AND EVOLUTION IN PATIENTS WITH LUMINAL BREAST CANCER
Luca Magnani
10.00 HRD IN BREAST CANCER.
BIOLOGICAL BACKGROUND.
Benedetta Pellegrino Lecture
10.20 INTRODUCTION Antonino Musolino
10.30 PRECLINICAL DATA AND TRANSLATIONAL RELEVANCE OF HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN BREAST CANCER
Violeta Serra
11.00 Discussion 11.10 Coffee break
11.40 HRD IN BREAST CANCER.
CURRENT CLINICAL APPLICATION Daniela Boggiani
Lecture
12.00 INTRODUCTION Antonino Musolino
12.10 SYNTHETIC LETHALITY AND BEYOND.
FUTURE PERSPECTIVES IN CLINICAL PRACTICE Suzette Delaloge
12.40 Discussion 12.50 Lunch
13.50 ASCO 2019.
UPDATES AND CONTROVERSIES IN
TRIPLE NEGATIVE BREAST CANCER TREATMENT Maria Vittoria Dieci
Giuseppe Curigliano 14.10 Discussion
14.25 UPDATES AND CONTROVERSIES IN LUMINAL-LIKE BREAST CANCER TREATMENT
Barbara Pistilli 14.45 Discussion
15.00 Coffee break
15.30 UPDATES AND CONTROVERSIES IN HER2-POSITIVE BREAST CANCER TREATMENT
Filippo Montemurro
16.00 Discussion
Lecture
16.10 INTRODUCTION Antonino Musolino
16.20 ARE WE HITTING A CEILING ON OUR THERAPEUTIC EFFECTIVENESS IN HER2-POSITIVE EARLY BREAST CANCER?
John P. Crown 16.50 Discussion
17.00 CONCLUSION Antonino Musolino
